| Budget Amount *help |
¥29,770,000 (Direct Cost: ¥22,900,000、Indirect Cost: ¥6,870,000)
Fiscal Year 2010: ¥9,620,000 (Direct Cost: ¥7,400,000、Indirect Cost: ¥2,220,000)
Fiscal Year 2009: ¥9,750,000 (Direct Cost: ¥7,500,000、Indirect Cost: ¥2,250,000)
Fiscal Year 2008: ¥10,400,000 (Direct Cost: ¥8,000,000、Indirect Cost: ¥2,400,000)
|
|---|
| Research Abstract |
We have reported a case of adult growth hormone deficiency (AGHD) accompanied with nonalcoholic steatohepatitis (NASH), in which GH replacement therapy drastically ameliorated NASH. Then, we have analyzed the prevalence of NAFLD/NASH in the patients with AGHD and found that NAFLD/NASH are frequently observed in AGHD and GH replacement therapy improved these conditions. Based on these results, we explored whether GH or IGF-I ameliorates general NASH using animal model. Interestingly, we found that GH particularly IGF-I ameliorated steatosis and fibrosis in the liver of the animal model, implicating a therapeutic application of IGF-I for general NASH.
|
